19. Statins in Portal Hypertension

  1. Roberto de Franchis MD, AGAF Professor of Gastroenterology Head
  1. Juan G Abraldes MD1,
  2. Vincenzo La Mura MD1 and
  3. Jaime Bosch MD2

Published Online: 17 NOV 2010

DOI: 10.1002/9781444393989.ch19

Portal Hypertension V: Proceedings of the Fifth Baveno International Consensus Workshop, Fifth Edition

Portal Hypertension V: Proceedings of the Fifth Baveno International Consensus Workshop, Fifth Edition

How to Cite

Abraldes, J. G., La Mura, V. and Bosch, J. (2011) Statins in Portal Hypertension, in Portal Hypertension V: Proceedings of the Fifth Baveno International Consensus Workshop, Fifth Edition (ed R. de Franchis), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444393989.ch19

Editor Information

  1. Department of Medical Sciences, University of Milan, and Gastroenterology 3 Unit, IRCCS Ca' Granda Ospedale Maggiore Policlinico Mangiagalli and Regina Elena Foundation, Milan, Italy

Author Information

  1. 1

    Hepatic Haemodynamic Laboratory, Liver Unit, Hospital Clinic, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), and Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

  2. 2

    Hepatic Haemodynamic Laboratory, Liver Unit, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain

Publication History

  1. Published Online: 17 NOV 2010
  2. Published Print: 14 JAN 2011

ISBN Information

Print ISBN: 9781444334494

Online ISBN: 9781444393989

SEARCH

Keywords:

  • a look into the future - new treatments on the horizon;
  • statins in portal hypertension;
  • liver cirrhosis, primary factors - portal hypertension, increasing resistance to portal blood flow;
  • ideal drug for portal hypertension - reducing portal pressure, decreasing intrahepatic vascular resistance;
  • use of statins in cirrhosis - expression of endothelial nitric oxide synthase (eNOS) and its activity at posttranslational level;
  • potential mechanisms, mediating - decrease in hepatic resistance by statins;
  • statins and liver circulation;
  • common bile duct ligation (CBDL) model;
  • statins in patients with cirrhosis;
  • potential of statins in patients with cirrhosis in RCTs - with clinical endpoints

Summary

This chapter contains sections titled:

  • The need for new drugs in portal hypertension

  • Rationale for the use of statins in cirrhosis

  • Statins in patients with cirrhosis

  • Other potential benefits of statins in cirrhosis

  • Future perspectives

  • References